Sugi Predict

Sugi Predict / Compounds / SCHEMBL4949146

SCHEMBL4949146

SCHEMBL4949146

Nc1ccnc(N2CC3CCC(C2)O3)n1

nearest known ligand 0.45

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
▸ MTOR P42345 10/20 0.45
▸ PIK3CA P42336 8/20 0.45
▸ KDM1A O60341 1/20 0.45
▸ MAP3K12 Q12852 2/20 0.39
▸ RICTOR Q6R327 1/20 0.39
▸ RPTOR Q8N122 1/20 0.39
▸ MAPKAP1 Q9BPZ7 1/20 0.39
▸ MLST8 Q9BVC4 1/20 0.39
▸ ACACB O00763 1/20 0.39
▸ PIK3CB P42338 1/20 0.38
▸ PIK3CG P48736 1/20 0.38
▸ PIK3C3 Q8NEB9 1/20 0.38
▸ OGA O60502 1/20 0.38
▸ MKNK1 Q9BUB5 1/20 0.38
▸ MKNK2 Q9HBH9 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL627878 0.81 MTOR (0.42) MTORPIK3CAMAP3K12ACACB
SCHEMBL26120616 0.81 MTOR (0.46) MTORPIK3CAKDM1AMAP3K12ACACB
SCHEMBL31513687 0.81 MTOR (0.46) MTORPIK3CAKDM1AMAP3K12ACACB
SCHEMBL2370406 0.80 MTOR (0.46) MTORPIK3CAMAP3K12PIK3CB
SCHEMBL23593409 0.79 KDM1A (0.46) PIK3CAKDM1AMAP3K12PIK3CBOGA
SCHEMBL10187282 0.79 DYRK1A (0.49) KDM1AACACBOGAMKNK1MKNK2
SCHEMBL29959199 0.78 KDM1A (0.42) PIK3CAKDM1AMAP3K12PIK3CBOGA
SCHEMBL23579408 0.78 KDM1A (0.42) PIK3CAKDM1AMAP3K12PIK3CBOGA
SCHEMBL23593427 0.78 KDM1A (0.39) MTORPIK3CAKDM1AMAP3K12PIK3CB
SCHEMBL15743008 0.78 KDM1A (0.35) MTORPIK3CAKDM1AMAP3K12RICTOR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250289801-A1 EGFR INHIBITORS BLUEPRINT MEDICINES CORPORATION 2025-09-18 — — US disclosed
CN-115135642-B Inhibitors of EGFR mutant forms 缆图药品公司 2025-03-04 — — CN disclosed
US-12172983-B2 EGFR inhibitors BLUEPRINT MEDICINES CORPORATION (US) 2024-12-24 — — US disclosed
US-11718602-B2 EGFR inhibitors BLUEPRINT MEDICINES CORPORATION (US) 2023-08-08 — — US disclosed
US-11718602-B2 EGFR inhibitors BLUEPRINT MEDICINES CORPORATION (US) 2023-08-08 — — US disclosed
US-11718602-B2 EGFR inhibitors BLUEPRINT MEDICINES CORPORATION (US) 2023-08-08 — — US disclosed
US-20230056541-A1 EGFR INHIBITORS BLUEPRINT MEDICINES CORPORATION 2023-02-23 — — US disclosed
US-20230056541-A1 EGFR INHIBITORS BLUEPRINT MEDICINES CORPORATION 2023-02-23 — — US disclosed
US-20230026209-A1 EGFR INHIBITORS BLUEPRINT MEDICINES CORPORATION 2023-01-26 — — US disclosed
US-20230026209-A1 EGFR INHIBITORS BLUEPRINT MEDICINES CORPORATION 2023-01-26 — — US disclosed
EP-2922851-B1 AMINOPYRIMIDINE COMPOUNDS AS INHIBITORS OF T790M CONTAINING EGFR MUTANTS GENENTECH INC (US) 2017-07-26 — — EP disclosed
EP-3181564-A1 AMINOPYRIMIDINE COMPOUNDS AS INHIBITORS OF T790M CONTAINING EGFR MUTANTS Genentech, Inc. (US) 2017-06-21 — — EP disclosed
EP-3181564-A1 AMINOPYRIMIDINE COMPOUNDS AS INHIBITORS OF T790M CONTAINING EGFR MUTANTS Genentech, Inc. (US) 2017-06-21 — — EP disclosed
US-20160016948-A1 AMINOPYRIMIDINE COMPOUNDS AS INHIBITORS OF T790M CONTAINING EGFR MUTANTS GENENTECH, INC. (US) 2016-01-21 — — US disclosed
US-20160016948-A1 AMINOPYRIMIDINE COMPOUNDS AS INHIBITORS OF T790M CONTAINING EGFR MUTANTS GENENTECH, INC. (US) 2016-01-21 — — US disclosed
US-20160016948-A1 AMINOPYRIMIDINE COMPOUNDS AS INHIBITORS OF T790M CONTAINING EGFR MUTANTS GENENTECH, INC. (US) 2016-01-21 — — US disclosed
EP-2922851-A1 AMINOPYRIMIDINE COMPOUNDS AS INHIBITORS OF T790M CONTAINING EGFR MUTANTS Genentech, Inc. (US) 2015-09-30 — — EP disclosed
WO-2014081718-A1 AMINOPYRIMIDINE COMPOUNDS AS INHIBITORS OF T790M CONTAINING EGFR MUTANTS GENENTECH, INC. (US) 2014-05-30 — — WO disclosed
WO-2014081718-A1 AMINOPYRIMIDINE COMPOUNDS AS INHIBITORS OF T790M CONTAINING EGFR MUTANTS GENENTECH, INC. (US) 2014-05-30 — — WO disclosed
WO-2008089034-A2 CYTOKINE INHIBITORS KEMIA, INC. (US) 2008-07-24 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230056541-A1 EGFR INHIBITORS EGFR, ERBB2, ERBB3 MTOR 243/4885PIK3CA 108/4885KDM1A 3493/4885
US-20230026209-A1 EGFR INHIBITORS EGFR, ERBB2, ERBB3 MTOR 243/4885PIK3CA 108/4885KDM1A 3493/4885
US-11718602-B2 EGFR inhibitors EGFR, ERBB2, ERBB3 MTOR 243/4885PIK3CA 108/4885KDM1A 3493/4885
US-12172983-B2 EGFR inhibitors EGFR, ERBB2, ERBB3 MTOR 243/4885PIK3CA 108/4885KDM1A 3493/4885
US-20160016948-A1 AMINOPYRIMIDINE COMPOUNDS AS INHIBITORS OF T790M CONTAINING EGFR MUTANTS EGFR, ERBB2, ERBB3 MTOR 336/4885PIK3CA 16/4885KDM1A 3732/4885
US-20250289801-A1 EGFR INHIBITORS EGFR, ERBB2, ERBB3 MTOR 243/4885PIK3CA 108/4885KDM1A 3493/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.